Zydus Cadila Generics Company Intelligence Report - Market Research Reports

Printer Friendly

Printed from http://www.researchandmarkets.com/reports/75077

Zydus Cadila Generics Company Intelligence Report

Description:

Cadila was founded in 1952, and was restructured in 1992 to become the Zydus Cadila Group. Cadila Healthcare, the Group's flagship company, was launched as an IPO in February 2000. The Zydus Group is aiming to become one of the top three healthcare companies in India and a global player. It has made forays into the US and EU markets, and other markets, such as Brazil, South Africa and Algeria. It started selling in Japan in 2007.

In July 2003, Zydus signed an agreement to acquire Alpharma SAS France, which it has renamed Zydus France. The acquisition gave the company an established distribution network and a pipeline of 109 generic registrations.

Zydus gained its first US ANDA approval, for atenolol tablets, in January 2005. The company has continued to push its presence in the US market since.

In May 2008, Zydus purchased the Spanish firm, Laboratorios Combix. The purchase enabled Zydus’ entry into the Spanish generics market. In November 2008, the firm acquired Etna Biotech in Italy, giving it a development platform for new vaccines.

In FY2009/10, ended 31st March 2010, Zydus reported consolidated gross sales worth Rs36,142 million (US$763.0 million). This was an increase of 23.9% over the prior year. Net profit increased by 66.6%, reaching Rs5,051 million (US$106.6 million).

At the end of 2009, the South African firm, Simayla, became wholly-owned by Zydus. Zydus had gained a 70% majority stake in Simayla in 2008, and acquired the remaining 30% in 2009.

In May 2010, Zydus and Abbott announced that they had entered into a strategic agreement focusing on the emerging markets. Abbott will licence 24 of Zydus' branded generics in 15 key emerging markets; the agreement includes an option for a further 40 products to be included.

Executive Summary

Espicom's generics company reports will help you to understand the dynamic and complex issues affecting the business of leading generic industry players. These informative reports provide an insight into the company, covering the structure of the business, the most recent quarterly and annual financial results, information on the company's active product lines and ANDA approvals, along with a review of major developments, such as M&A activity, strategic alliances, and litigation.

Contents:

1.Executive Summary 2.Introduction 3.Products 4.Financial Results 5.Major Developments 6.Contact Details

Companies Mentioned

Evolupharn Aerocid Bharat Serums and Vaccines Mayne Pharma Venus Remedies Mallinckrodt MoU with Zambon Alpharma France Cadila Healthcare Banyan Chemicals. Byk Gulden (Altana) German Remedies Recon Healthcare

Ordering:

Order Online - visit http://www.researchandmarkets.com/reports/75077

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

Page 1 of 2
Printed 12/02/2012 11:59:35

Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to
646-607-1907 (from USA) or +353 1 6849977 (from Rest of World). If you have any questions please email help@researchandmarkets.net

Order information
Please verify that the product information is correct and select the format you require.


Product Name:
Zydus Cadila Generics Company Intelligence Report
Web Address:
http://www.researchandmarkets.com/reports/75077
Office Code:
OC8IHINLSNNSS

Report formats
Please enter the quantity of the report format you require.

Format	Quantity	Price
Electronic (PDF) - Single User		€245.00
Electronic (Online Access) - Enterprisewide		€1,595.00
Hard Copy		€245.00 + EUR€ 25.00 Shipping/Handling *
Electronic (Online Access) - Single User		€245.00
Electronic (PDF) - Enterprisewide		€1,595.00

* Shipping/Handling is only charged once per order.

Contact information
Please enter all the information below in BLOCK CAPITALS.


	First Name:	Last Name:
	Email Address:
	Job Title:
	Organisation:
	Address:
	City:
	Postal/Zip Code:
	Country:
	Phone Number:
	Fax Number:

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)

Page 2 of 2
Printed 12/02/2012 11:59:35

Payment information

Please indicate the payment method you would like to use by selecting the appropriate box.

Pay by Credit Card:

	American Express
	Diners Club
	Master Card
	Visa


Cardholder's Name:

Cardholder's Signature:

Expiry Date:	/

Card Number:

CVV Security Code:

Issue Date:	/ (Diners Club only)

Pay by Check:

Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

Pay by Wire Transfer:

Please transfer funds to:


Account number:	83313083
Sort code:	98-53-30
Swift code:	ULSBIE2D
IBAN number:	IE78ULSB98533083313083
Bank Address:	Ulster Bank, 27-35 Main St, Blackrock, Co. Dublin, Ireland.

If you have a Marketing Code please enter it below:
	Marketing Code:

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)